Madrigal has made three in-licensing deals since July 2025, picking up multiple potential MASH therapeutics. Read why MDGL ...
Company advances its leadership in MASH with an expanded pipeline, which now includes more than 10 programs at multiple ...
Fourth-quarter and full-year 2025 Rezdiffra® (resmetirom) net sales of $321.1 million and $958.4 million, respectively As of year-end 2025, more ...
Madrigal Pharma was the first drugmaker to bring a treatment for metabolic dysfunction-associated steatohepatitis (MASH) to market, and has now signed a major alliance with China's Ribo Life Science ...
Madrigal shares fell 11% despite again topping consensus sales numbers. Elsewhere, Daiichi Sankyo named a new research chief ...
Madrigal Pharmaceuticals (NasdaqGS:MDGL) reports nearly US$1b in first full year Rezdiffra sales. The company launches Rezdiffra in Germany, its first market in Europe. Madrigal secures extended US ...
After several quarters on a steady sales roll as the world’s first treatment for metabolic dysfunction-associated ...
Madrigal Pharmaceuticals (MDGL) has drawn investor attention after recent share price moves, with the stock showing a 1 day return of 1.92% and a 7 day return of 2.70% heading into this week. See our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results